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 Genetic mutations are important risk factors for ovarian cancer; with certain mutations 
increasing a woman’s risk for ovarian cancer by as much as 50%. The search for these mutations 
has recently been led by large projects utilizing the genetic information of thousands of 
individuals. These studies have been able to find suspected oncogenic mutations such as the 
Single Nucleotide Polymorphism(SNP) rs3814113, but have been unable to prove causal 
relationships due to the inability to incorporate hard to quantify data. Smaller studies however 
are able to incorporate such data and provide definitive results. This study focused on finding 
evidence to corroborate the relationship between rs3814113 and ovarian cancer risk. This study 
investigated the lifestyles, personal history, family history, and medical history as well as the 
genotype of twenty patients to determine their individual risk for ovarian cancer. This 
information was used in a series of statistical tests to explore the possibility that each patient’s 
risk for ovarian cancer is affected by the presence of rs3814113. In particular the allelic 
frequencies were calculated and compared to the general population, T-tests were conducted to 
determine significant differences between groups, and the presence and risk of ovarian cancer 
were compared to the presence of rs3814113. None of the statistical tests performed were able to 
provide evidence of a link between rs3814113 and ovarian cancer risk, thus this study could find 
no evidence of rs3814113 having an effect on ovarian cancer risk. 
 
Current Understanding of Ovarian Cancer 
  Ovarian cancer comprises 3% of novel cancer cases in women(Jemal, Siegel et al. 2008). 
This cancer accounts for 5.7% of mortality among female cancer patients, estimated to be 15,000 
women in 2008 alone and has a mean survival time of 5 years(Jemal, Siegel et al. 2008). Due to 
the lethality of this cancer it is among the most well studied. Mutations commonly found in the 
tumors, the effects of the cancer, and the antigens it creates are all foci of research. The fruits of 
this research, genetic testing, hormone replacement therapy, and cancer antigen(CA) 125 testing 
have saved thousands of lives and helped reduced ovarian cancer’s lethality. Despite these 
previous efforts, questions still remain regarding ovarian cancer. The most sought after of these 
questions are the mutations responsible for ovarian cancer.  
 
Known mutations for Ovarian Cancers 
The Breast Cancer Associated(BRCA) genes are the most important oncogenes found to 
be associated with ovarian cancer. BRCA mutations occur in 40% of familial ovarian cancers 
(Palma, Ristori et al. 2006) and their presence drastically changes the likelihood of a woman 
contracting ovarian cancer over the course of her lifetime. A woman without BRCA mutations 
normally has a 1.8% risk of developing ovarian cancer, but if a woman has a severe mutation in 
her BRCA genes then her risk of contracting ovarian cancer increases to 44%(Palma, Ristori et 
al. 2006; Bordeleau, Panchal et al. 2009). This radical change in risk can be explained through 
BRCA’s suspected function as a component of DNA repair. DNA repair pathways thwart cancer 
development by preventing cancer causing mutations from accumulating. The BRCA genes 
encode for proteins that are integral to these pathways(Tutt and Ashworth 2002). The BRCA 
genes produce proteins that interact with RAD51,and BRCA 1 is assumed to act as a scaffold 
protein for DNA repair complexes(Palma, Ristori et al. 2006). The exact operation of these 
proteins is not well understood at this point, but mutations in these genes clearly make their 
products less effective or completely inoperable. Without the BRCA proteins, the DNA repair 
pathway in the ovaries does not function as effectively and other cancer causing mutations are 
more likely to develop(Palma, Ristori et al. 2006). 
 
Finding other Cancer Related Mutations 
Many scientists have hypothesized that BRCA may not be the only significant ovarian 
cancer causing mutation. As explained earlier, hereditary BRCA mutations occur in a significant 
portion of familial ovarian cancer, but not in all of them. 60% of familial ovarian cancer cases do 
not involve hereditary BRCA mutations, yet these families have recurring ovarian cancer in their 
history. This simple fact has sparked many investigations to find another significant mutation 
related to the cancer. While each diagnosis of cancer has its own unique set of mutations(Hainaut 
2001), different cancers do have common mutations. Certain SNPs common to many forms of 
cancer and it has been found that the only SNP’s common to ovarian cancer were those involved 
with breast cancer as well (Quaye, Tyrer et al. 2009). Another study used cDNA microarrays to 
find similar gene expression across ovarian cancer tumors(Jazaeri 2009). A study focused on the 
BRCA Interacting Protein(BRIP) as a possible contributor to ovarian cancer(Song, Ramus et al. 
2007). These studies utilized large datasets, but none were able to establish a strong correlation 
between a particular mutation and ovarian cancer. These studies were able to identify what may 
be mutations with low genetic penetrance, but lacked the data to prove it. Genetic penetrance 
refers to the likelihood of a gene to affect the phenotype of the individual with lower penetrance 
equating to a lower effect that gene has on the individual’s phenotype. Often these genes can be 
present in an individual but may not affect the carrier’s phenotype, making a cause and effect 
relationship difficult to establish. Even BRCA gene mutations, which have the highest penetrance 
of ovarain cancer causing mutations, only bestows a cancer risk of 39%. 
 
Genome Wide Association Studies as a solution 
To combat the problem of finding more potentially cancer causing mutations, scientists 
have turned to utilizing Genome Wide Association Studies(GWAS). These studies function by 
collecting large sample groups and dividing them by their phenotypic differences. The different 
phenotypes then have their entire genome sequenced and their genetic variations are recorded. 
The prevalence of genetic variations among certain groups can then be used to create correlations 
between a specific phenotype and genetic variations despite low genetic penetration(Manolio 
2010). The most recent GWAS to produce significant results was done by this past year and it 
involved 20,000 participants. This study found a correlation between the C allele of the SNP 
rs3814113 and cancer suppression(Song, Ramus et al. 2009). 
Little information exists concerning the function of  rs3814113, but what little 
information does exist supports the hypothesis that it could affect ovarian cancer risk. 
Rs3814113 is an SNP found in the basonuclin 2 gene. Scientists believe this gene increases the 
production of ribosomal RNA (rRNA), as shown by the shared homology between Basonuclin 2 
and other known rRNA promoters(Vanhoutteghem, Djian et al. 2004). rRNA is one of the 
components of ribosomes, the cellular machinery that creates proteins. If basonuclin 2 controls 
the production of cellular machinery then it could function as a cancer suppressing gene by 
altering the concentration of proteins; particularly if those proteins are related to cell replication. 
Basonuclin 2 has already been implicated in the progression of normal esophageal cells into a 
condition known as “Barret’s Esophagus” and the condition’s further progression into 
esophageal cancer(Akagi, Ito et al. 2009). Furthermore, basonuclin 2 is only expressed in 
epidermal cells and sex precursor cells such as the ovaries(Vanhoutteghem, Djian et al. 2004). 
Given the putative function of the gene, its known association with esophageal cancer, and it’s 
expression in only two tissues makes the basonuclin 2 an attractive choice for an ovarian cancer 
contributing or suppressing mutation. However; no proof has been discovered that supports a 
causal relationship between basonuclin 2 or rs3814113, and ovarian cancer risk.  
 
Inconclusiveness of Genome Wide Association Studies 
Unfortunately due to the weaknesses of GWAS studies only a proposed correlation exists 
between  rs3814113 and ovarian cancer(Manolio 2010).  The main advantage and disadvantage 
of a GWAS is the volume of information collected. The large amount of data collected can be 
useful for finding correlations between phenotypes and mutations but it must make thousands of 
comparisons to reach any results. The volume of comparisons made degrades the power of the 
test overall and thus less able to prove a connection, requiring that any results be incredibly 
unlikely to be considered significant. This fact results in GWAS studies being used mostly for 
finding correlations rather than causations between mutations and phenotypes. 
 Aside from the large number of comparisons made, GWAS studies also leave out large 
amounts of information on each individual subject preventing them from proving causation. 
GWAS studies focus almost solely on a patient’s genetic information to reach it’s conclusions. 
However; each patient also has a medical history and family history that are significant but often 
difficult to analyze in bulk. These data are used to screen possible participants or not 
incorporated into the GWAS. Ramus et al. encountered this problem in their most recent project 
when they were unable to access detailed histories for all their patients. Without the additional 
information regarding patient histories the project had difficulty analyzing what other risk factors 
contributed to the pathology of each patient.  Thus despite doing a follow up study regarding 
BRCA and rs3814113, the study could not find any evidence supporting anything greater than a 
correlation between the two mutations(Ramus SJ 2010). Because a GWAS study ignores so 
much of the data it has the potential to overlook important trends, and weakens the overall 
findings. 
 
Smaller Studies to Test Connections 
While large studies can yield valuable information they can often exclude relevant data 
that maybe important to prove causation. However large studies are useful for establishing 
correlations that can be further tested by smaller projects. Smaller projects can include 
information larger studies would have difficulty processing such as detailed family and patient 
histories. Smaller research projects can also invest more effort per sample and can adapt to 
unexpected findings in the data. Also, these smaller projects are cheaper and so do not represent 
as large a potential loss. For all these reasons, smaller projects such as this one are necessary to 
explore the findings of larger studies. 
This project in particular will focus on investigating the findings of a precios GWAS that 
found a correlation between the SNP rs3814113 and cancer suppression. This study will use 
difficult to quantify information such as the patient and family histories of the subjects. By 
including this information this study will be able to determine the expected risk of the patients 
for ovarian cancer and how the presence of rs3814113 changed those risks. With these risk 
comparisons this study will be able to determine if the previously found correlation was truly 
significant. 
Materials and Methods: 
Selecting Samples and Amplifying DNA 
 Twenty blood samples were selected from stock at the McDonald cancer research lab. Of 
these twenty samples ten were from ovarian cancer patients and ten were from patients without 
ovarian cancer. The selected samples were the newest available to the lab and accordingly were 
the least degraded by storage, but the patients were sampled randomly at the time of diagnosis. 
 Once selected, these samples were amplified 
through PCR processing to increase the concentration 
of the SNP rs3814113. The SNP had to be amplified so 
there would be enough genetic material available for 
sequencing later in the experiment. The cycles of the 
PCR process can be found in table 1, 
and the recipe for the PCR mixture can 
be found in table 2. The forward primer 
used was 5’-
TTTCCTGTTTTCCTCCATGC-3’ and 
the reverse primer used was 5’-
AGGCTCTAGGGAAAGCCAAG-3’. 
The primers used were specifically engineered to bind 86 bases upstream of the target SNP and 
299 bases downstream of the target SNP. This was done so the amplified DNA would be large 




Purifying and Sequencing the DNA Product 
 Once the samples were successfully amplified the desired DNA was extracted from the 
rest of the cellular contents for sequencing. The PCR product was loaded into a 2% agarose gel 







95 120 1 
95 30 30 
52 30 30 
72 60 30 
72 420 1 
Table 2: PCR Cocktail Mix 




Distilled H2O 10.54 263.5 
Buffer 4 100 
MgCl2 .96 24 
Forward Primer 1 25 
Reverse Primer 1 25 
dNTPs 1 25 
TAQ .5 12.5 
for electrophoresis. As the DNA proceeds through the gel the smaller fragments move more 
quickly while the larger fragments progress more slowly causing the formation of bands. These 
bands each contain DNA fragments of a particular 
size. The gel was allowed to run for two hours at 
which point the target band of 386 bases became 
distinct. Afterwards the bands were cut from the 
gel using a razorblade. Once excised the gel band 
was dissolved according to the directions found in 
the QIAquick PCR purification kit and the DNA 
was purified in an elution column. The purified 
DNA solution was then loaded into labeled vials 
and shipped to Operon Sequencing Incoporated 




 Once the sequenced results were returned each sample was evaluated to determine its 
genotype. The frequencies of these genotypes were then recorded. Population frequencies of 
these genotypes were then collected from the International HapMap project, and used to 
calculate the likelihood of the genotypic concentrations among the pathologic groups. 
Patients were split into groups based upon first their pathology and then their genotype to 
perform all statistical tests. T-tests were also performed to determine if there were any 
differences between the last menstrual period(LMP) and the age of diagnosis(AOD) among the 
Figure 1: The base signals of a heterozygous 
patient for the SNP rs3814113 
genotypic groups and the pathologic groups. Afterwards the prior medical and familial histories 
of the subjects were collected and used to calculate their individual risk of ovarian cancer using 
the online program from the Siteman Cancer Center. Race, age, prior cancer history, Familial 
cancer history, smoking, and history of hormone replacement therapies were used as criteria in 
calculating the patient’s individual risk rating. These risk ratings were used to see if all genotypic 




 The 20 patients and their sequences were grouped initially by their pathology into two 
groups: those who had developed ovarian cancer and those who had not developed it. Each group 
then had their genotypic frequencies and the likelihood of these frequencies calculated using 
population frequencies provided by the International HapMap project. The healthy patients were 
not found to be statistically different from the general population in their genotypic frequencies, 
with a heterozygous frequency of 30% and no individuals homozygous for the C allele of the 
SNP. The Cancer group however differed significantly from the expected genotypic ratios with 
all but two subjects being heterozygous for the C allele. The resulting binomial distribution 
resulted in a p-value of .0317, thus showing this group had significantly more heterozygotes than 
expected and the P < .05 level. The allelic frequencies also had interesting result. The control 
group had significantly fewer C alleles than expected with a p-value of .0288. The cancer groups 
allelic frequencies did not significantly differ from the population’s frequencies. 
Next the age and diagnosis for ovarian cancer and the age at last menstrual period(LMP) 
were evaluated between the two groups. Both of these tests separated subjects into two groups of 
ten based on their pathology. In each case the two sample t-tests used assumed unequal variance 
between the groups, and were two tailed to find differences between the two groups regardless of 
what those differences were. Neither test found a statistically significant difference between the 
two groups at the p-value = .05 level.  
Next the twenty patients were divided into group based on their 
genotype, this division resulted in one group of 9 homozygous 
individuals and one group of 11 heterozygous individuals. The t-tests 
described above were then repeated using these new groups. Again 
neither test found any significant difference between the two groups. 
All results from t-tests can be found in table 3. 
Finally the women were evaluated on their individual cancer risk as calculated by the 
Siteman Cancer Center. These cancer risks were then used to create a table of counts that 
counted the number of individuals with below average, average, and above average cancer risk in 
each genotypic group and each pathologic group. All groups were found to have roughly a 4:6:9 
ratio. The results can be found in table 4. 
Table 4: Cancer Risk Counts. 
Risk     TT     CT Cancer Control Total 
Below 
Average 
3 1 2 2 4 
Average 2 5 4 3 6 
Above 
Average 
4 5 4 5 9 
 
 
Discussion and Conclusion 
 Previous studies by Song et al. have supported the correlation between the C allele of 
rs3814113 and reduced cancer risk, this study however did not find any evidence to support 
Table 3: t-tests and 
results  













those findings. When the genotypic frequencies of the two groups were compared to the 
population averages from the International Hap Map project the cancer group was found to 
significantly diverge from the population averages. The cancer group showed a much higher 
prevalence of heterozygotes than expected, with only a 3.17% chance of such a result occurring. 
The expected result had been that the control group would have a higher prevalence of 
heterozygotes than the cancer group or the general population. However this experiment has 
displayed the opposite result were the supposedly cancer suppressing mutation has been found to 
be more prevalent among the cancer group. The allelic frequencies were likewise surprising in 
that the C allele was found to be in significantly lower concentration among the control group 
than expected.  
 The t-tests showed no evidence to support the C allele of rs3814113 as a cancer 
suppressing mutation. The T-test for age of diagnosis showed no significant difference between 
the cancer and control groups. This result indicates that there was no significant difference in 
onset of the disease and suspected onset of the disease between the two pathologic groups. The 
second T-test with subjects separated by genotype also resulted in no significant difference 
between the groups. Thus, there is no significant difference between the onset of ovarian cancer 
for the two genotypes. When these groups were used to compare the age at last menstrual period 
there was likewise no significant difference between the groups. Age of diagnosis and LMP are 
useful tools used to determine if there are important biological differences at work within 
different patients or groups of people. For instance had there been a difference in the age of onset 
between the genotypic groups then it could be argued that the presence of the mutations either 
caused or prevented the onset of cancer. Likewise a difference in LMP could have suggested a 
change in the gynecological function between the two groups due to the presence of the 
mutation. But in this experiment there was no significant difference in LMP regardless of 
whether the 20 women were divided by pathology or genotype. 
 Finally the cancer risk of each patient was evaluated using the cancer risk calculator at 
the Siteman Cancer Center’s website. The prevalence of each risk category was calculated for 
four different groups, the TT genotype, the CT genotype, the Cancer group, and the control 
group. These ratios were then compared against each to determine if there was a significant 
difference.  Interestingly the ratios across all four groups matched the ratios for the entire group. 
This result means that all groups had the same ratio of high to low risk cancer subjects, 
regardless of pathology or genotype and they matched the ratios of the group as a whole. This 
constant ratio means that currently the presence of the genotype or the pathology of the patients 
has any effect on the expected ratio of cancer risk. 
 Between the lack of statistically significant differences for age of diagnosis or LMP 
between the pathologic or genotypic groups, the uniform cancer risk ratios across the groups, and 
the higher than expected prevalence of the CT genotype in the cancer group this study can say 
that it did not find any evidence supporting the C allele as a cancer suppressing mutation. 
 This study did have some weaknesses. First, this study was very small. While a small 
study can invest more hours work into investigating each sample than a larger study, these small 
numbers are susceptible to fluctuations in the data. For example, there was a 3.17% chance that 
of the ten cancer patients that 8 or more would be heterozygous for the cancer suppressing allele. 
While this likelihood is small there is a possibility this result is in fact a type I error, and that the 
sample group collected was not representative of the actual groups of interest. Likewise, the 
other results could also be affected by fluctuations in the data or the sample group. If this 
experiment were repeated again it should be done on a larger scale. Thirty or more cancer 
patients and thirty women for a control group would provide a large enough sample where 
groups could be more safely assumed to match the larger population. Larger sample sizes also 
allow for the use of more powerful statistical tests and greater power in the tests used. A large 
sample group also gives greater variability to the sample groups that may allow other factors to 
be tested, for example this study could not evaluate the severity of the cancer across genotypic 
groups because eight of the ten cancer patients were heterozygous for the mutation.  
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